Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | CA12 | O43570 | 2/20 | 0.33 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | CA9 | Q16790 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.30 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7354829 | 0.67 | KMT2A (0.47) | MAPTALDH1A1KDM4EKMT2AMEN1 | |
| SCHEMBL3452601 | 0.66 | CA12 (0.61) | MAPTALDH1A1KDM4EKMT2ACA12 | |
| SCHEMBL29360628 | 0.64 | ALDH1A1 (0.39) | MAPTALDH1A1NPSR1KDM4EMCOLN3 | |
| SCHEMBL28228185 | 0.61 | MEN1 (0.38) | MAPTALDH1A1NPSR1KDM4EMCOLN3 | |
| SCHEMBL2461404 | 0.61 | SMN1; SMN2 (0.33) | MAPTALDH1A1NPSR1KDM4EMCOLN3 | |
| SCHEMBL28177984 | 0.59 | ALDH1A1 (0.31) | ALDH1A1 | |
| SCHEMBL7124293 | 0.59 | SMN1; SMN2 (0.33) | MAPTALDH1A1NPSR1KDM4EMCOLN3 | |
| SCHEMBL30722257 | 0.59 | SMN1; SMN2 (0.33) | MAPTALDH1A1NPSR1KDM4EMCOLN3 | |
| SCHEMBL1837999 | 0.59 | L3MBTL3 (0.47) | MAPTALDH1A1NPSR1KDM4EMCOLN3 | |
| SCHEMBL1827648 | 0.58 | SMN1; SMN2 (0.54) | ALDH1A1KDM4EL3MBTL1L3MBTL3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060142285-A1 | Pharmaceutical composition comprising N-aryl N' morpholino/piperidino thiocarbamide derivatives for treating and preventing diabetes, diabetic complications, insulin resistance and insulin resistance syndrome | KIM SUNG-JIN | 2006-06-29 | — | — | US | claimed |
| US-7820656-B2 | Pharmaceutical composition comprising N-aryl N′ morpholino/piperidino thiocarbamide derivatives for treating type II diabetes | Kim, Sung-jin (KR) | 2010-10-26 | — | — | US | disclosed |
| US-7820656-B2 | Pharmaceutical composition comprising N-aryl N′ morpholino/piperidino thiocarbamide derivatives for treating type II diabetes | Kim, Sung-jin (KR) | 2010-10-26 | — | — | US | disclosed |
| US-7820656-B2 | Pharmaceutical composition comprising N-aryl N′ morpholino/piperidino thiocarbamide derivatives for treating type II diabetes | Kim, Sung-jin (KR) | 2010-10-26 | — | — | US | disclosed |
| US-20060142285-A1 | Pharmaceutical composition comprising N-aryl N' morpholino/piperidino thiocarbamide derivatives for treating and preventing diabetes, diabetic complications, insulin resistance and insulin resistance syndrome | KIM SUNG-JIN | 2006-06-29 | — | — | US | disclosed |
| US-20060142285-A1 | Pharmaceutical composition comprising N-aryl N' morpholino/piperidino thiocarbamide derivatives for treating and preventing diabetes, diabetic complications, insulin resistance and insulin resistance syndrome | KIM SUNG-JIN | 2006-06-29 | — | — | US | disclosed |
| US-20060142285-A1 | Pharmaceutical composition comprising N-aryl N' morpholino/piperidino thiocarbamide derivatives for treating and preventing diabetes, diabetic complications, insulin resistance and insulin resistance syndrome | KIM SUNG-JIN | 2006-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142285-A1 | Pharmaceutical composition comprising N-aryl N' morpholino/piperidino thiocarbamide derivatives for treating and preventing diabetes, diabetic complications, insulin resistance and insulin resistance syndrome | GPR119, INSR, MTPN | MAPT 4321/4885ALDH1A1 2865/4885NPSR1 1943/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.